Boldenone Undecylenate
Long-acting testosterone derivative with exceptional 14-day half-life for stable compound levels.
Boldenone Undecylenate
Boldenone Undecylenate is a sterile oil-based injectable preparation of boldenone esterified with undecylenic acid, presented at 250 milligrams per millilitre in a 10 mL multiple dose vial. The eleven-carbon ester gives this preparation the longest release profile in the injectable range.
Structural Profile
Boldenone is 1-dehydrotestosterone: testosterone bearing an additional double bond between carbons 1 and 2. This modification increases anabolic activity while reducing androgenic potency and markedly lowering affinity for the aromatase enzyme. With the undecylenate ester at the 17-beta position the molecular formula is C30H44O3, molar mass 452.67 g/mol, registered under CAS number 13103-34-9.
Esterification and Release
The undecylenate chain contains eleven carbons and an unsaturated bond, making it the most lipophilic ester in routine use. Partition from the oil depot into plasma is exceptionally slow and sustained, with measurable serum concentrations persisting for several weeks after a single administration.
Pharmacokinetic Profile
The elimination half-life is approximately 14 days, the longest among the injectable preparations in this catalogue. Serum concentrations build gradually over the initial period of administration and remain remarkably stable thereafter. The urinary detection window extends to approximately 5 months.
Mechanism of Action
Boldenone binds the cytoplasmic androgen receptor and the activated complex regulates transcription at androgen response elements, promoting structural protein synthesis and nitrogen retention in skeletal muscle. The 1,2-double bond reduces the rate of aromatisation to approximately half that of testosterone, so oestrogenic conversion occurs but is limited. Boldenone is also associated with an increase in erythropoiesis mediated by stimulation of renal erythropoietin production.
Manufacturing and Sterility
Each production lot is released against the complete pharmaceutical testing protocol: HPLC identity confirmation and purity analysis with a specification of not less than 98 percent, verification of concentration against label claim within 5 percent, sterility testing in accordance with USP <71>, bacterial endotoxin quantification by LAL assay below 0.25 EU/mL, and particulate matter inspection in accordance with USP <788>. A Certificate of Analysis is issued for every lot.
Quality Assurance
Every batch of Boldenone Undecylenate produced by Biomedica undergoes the complete pharmaceutical release testing protocol before distribution. This includes HPLC compound identity confirmation and purity analysis (specification: ≥98%), concentration verification (specification: ±5% of label claim), sterility testing per USP <71>, bacterial endotoxin quantification by LAL assay (specification: <0.25 EU/mL), and particulate matter inspection per USP <788>. A Certificate of Analysis is issued for every production lot.
Authentication
Each unit of Boldenone Undecylenate carries a unique authentication code on its outer packaging. This code can be verified instantly on our Authentication page to confirm the product is genuine Biomedica stock.